IPO for EU's fastest-growing parallel trade company

Denmark-based Abacus Medicine is preparing an initial public offering (IPO) on the Prime Standard of the Frankfurt Stock Exchange.

Abacus calls itself Europe’s fastest-growing pharmaceutical parallel trade company with a 37% revenue compound annual growth rate between 2016 to 2018, along with robust margin development.

The parallel trade business model is based on the principle of free movement of goods in the European Union’s (EU) single market, where the same pharmaceutical product is often available at different prices in different countries.